Another study conducted in vivo and in vitro showed that peptide FNIII14, which can inhibit the effects of TNIIIA2 through inactivation of β1-integrins, increased the susceptibility of GBM cells to TMZ by suppressing O6-methylguanine-DNA methyltransferase (MGMT) expression (138). This evidence concerns the gene MGMT and glioblastoma.